These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10389130)

  • 1. Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation.
    Harwood JS; Gould FK; McMaster A; Hamilton JR; Corris PA; Hasan A; Gennery AR; Dark JH
    Pediatr Transplant; 1999 May; 3(2):100-3. PubMed ID: 10389130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
    Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
    J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Epstein-Barr virus (EBV) antibody screening of organ donors for allocation of organs to EBV serostatus matched recipients.
    Lazda VA
    Transplant Proc; 2006 Dec; 38(10):3404-5. PubMed ID: 17175286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients.
    Boyle GJ; Michaels MG; Webber SA; Knisely AS; Kurland G; Cipriani LA; Griffith BP; Fricker FJ
    J Pediatr; 1997 Aug; 131(2):309-13. PubMed ID: 9290623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center.
    Dogan B; Sema YA; Bora K; Veysel U; Benan D; Ezgi KT; Gozde AK; Demir D; Ozsan N; Hekimgil M; Zumrut SB; Miray K; Funda C; Sema A
    J Med Virol; 2024 Jun; 96(6):e29767. PubMed ID: 38932460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disorders: a preventable complication of solid organ transplantation?
    Webber SA
    Pediatr Transplant; 1999 May; 3(2):95-9. PubMed ID: 10389129
    [No Abstract]   [Full Text] [Related]  

  • 8. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY; Tait B; Levvey B; Griffiths A; Esmore DS; Snell GI; Williams TJ; Kotsimbos TC
    Transplantation; 2004 Jul; 78(2):205-10. PubMed ID: 15280679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients.
    Haque T; Thomas JA; Falk KI; Parratt R; Hunt BJ; Yacoub M; Crawford DH
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1169-72. PubMed ID: 8683203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
    Verschuuren E; van der Bij W; de Boer W; Timens W; Middeldorp J; The TH
    J Med Virol; 2003 Feb; 69(2):258-66. PubMed ID: 12683416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.
    Heldman MR; Edlefsen KL; Pepper G; Kapnadak SG; Rakita RM; Fisher CE; Limaye AP
    Transpl Infect Dis; 2022 Dec; 24(6):e13933. PubMed ID: 36000190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events.
    Haque T; Thomas JA; Parratt R; Hunt BJ; Yacoub MH; Crawford DH
    Transplantation; 1997 Oct; 64(7):1028-34. PubMed ID: 9381525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients.
    Gratama JW; Oosterveer MA; Lepoutre JM; van Rood JJ; Zwaan FE; Vossen JM; Kapsenberg JG; Richel D; Klein G; Ernberg I
    Transplantation; 1990 Apr; 49(4):725-30. PubMed ID: 2158159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplant lymphoproliferative disorder in liver allograft biopsies: a comparison of three methods for the demonstration of Epstein-Barr virus.
    Lones MA; Shintaku IP; Weiss LM; Thung SN; Nichols WS; Geller SA
    Hum Pathol; 1997 May; 28(5):533-9. PubMed ID: 9158700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA; Breinig MC; McKnight JL
    Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients.
    Smets F; Bodeus M; Goubau P; Reding R; Otte JB; Buts JP; Sokal EM
    J Hepatol; 2000 Jan; 32(1):100-4. PubMed ID: 10673073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.